Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: INDIVIDUALIZED THERAPY Clear all
Completed No phase listed Observational Results available

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

NCT02060890
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

NCT03960008
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Burlington, Massachusetts • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Early Phase 1 Interventional

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

NCT07025226
View directory record Official record
Conditions
Glioma
Interventions
Biospecimen Collection, Dasatinib, Fisetin, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Quercetin, Temozolomide, Topoisomerase-1 Inhibitor LMP744, Single Agent Therapy
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional

Transitional Intervention for Hyperacusis in Autism

NCT07798297
View directory record Official record
Conditions
Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
Interventions
Transitional Intervention for Hyperacusis in Autism
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Enhanced Dialectical Behavior Therapy for Adolescents

NCT07256496
View directory record Official record
Conditions
Suicidality
Interventions
Enhanced DBT-A
Behavioral
Lead sponsor
Compass Behavioral Health
Other
Eligibility
13 Years to 25 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Individualized Functional Connectivity Targeting in aiTBS for Depression

NCT05680727
View directory record Official record
Conditions
Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder, Psychiatric Disorder
Interventions
transcranial magnetic stimulation
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Individualized Treatments in Adults With Relapsed/Refractory Cancers

NCT06024603
View directory record Official record
Conditions
Refractory Cancer, Relapsed Cancer
Interventions
Drug Sensitivity Test (DST)
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Not listed No phase listed Observational

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

NCT02160366
View directory record Official record
Conditions
Advanced Cancers
Interventions
Biomarker Research
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

NCT02460835
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Adaptive Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 26, 2026, 5:30 AM EDT
Withdrawn Not applicable Interventional

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

NCT05488626
View directory record Official record
Conditions
Stage III Non-small Cell Lung Cancer
Interventions
Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy, Immunotherapy
Device · Drug
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Not applicable Interventional

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

NCT05764720
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Daily Adaptive External Beam Radiation Therapy
Radiation
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • Duarte, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated No phase listed Observational

An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)

NCT03955276
View directory record Official record
Conditions
Hematologic Cancer
Interventions
Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

NCT07022470
View directory record Official record
Conditions
Cervical Cancers
Interventions
3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease

NCT04584528
View directory record Official record
Conditions
Sickle Cell Disease, Genetic Disease, Hematologic Diseases, Anemia, Sickle Cell
Interventions
Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Oakland, California • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

NCT02076997
View directory record Official record
Conditions
Cancer
Interventions
Methotrexate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 22 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT01620216
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Antitumor Drug Screening Assay, Dasatinib, Idelalisib, Laboratory Biomarker Analysis, Pacritinib, Pharmacological Study, Ponatinib, Ponatinib Hydrochloride, Ruxolitinib, Sorafenib, Sorafenib Tosylate, Sunitinib, Sunitinib Malate
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 26, 2026, 5:30 AM EDT
Withdrawn Phase 1 Interventional

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

NCT03895658
View directory record Official record
Conditions
Unipolar Depression
Interventions
MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 26, 2026, 5:30 AM EDT
Withdrawn Early Phase 1 Interventional

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET-Adaptive RT, Erlotinib, Crizotinib
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NCT02135042
View directory record Official record
Conditions
EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
Interventions
Bone Scan, Cisplatin, Clinical Observation, Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Quality-of-Life Assessment
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
197
States / cities
Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Research on Individualized Treatment for Alcoholism

NCT00523133
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone, Broad Spectrum Treatment, Motivational Enhancement Treatment
Drug · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2007 · Synced Sep 26, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT00429858
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
S-1, gemcitabine hydrochloride
Drug
Lead sponsor
Andrew Ko
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 2 Interventional

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

NCT03897881
View directory record Official record
Conditions
Melanoma
Interventions
mRNA-4157, Pembrolizumab
Drug · Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
17
States / cities
Tucson, Arizona • San Francisco, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 26, 2026, 5:30 AM EDT